Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Drug Development: Making the impossible possible

Juniper Pharma Services
Posted on: 16 Nov 17

THE Advancing Drug Development Forum has confirmed a prestigious line-up of leading industry voices to speak at its inaugural event.


Taking place on November 30, 2017 in Boston, USA, the forum will see pharmaceutical experts and scientists from across the globe come together to exchange ideas and experiences and conduct a deep dive into the real-world challenges of drug development in the biotech and pharma sectors. 


The speakers and panellists will explore new solutions, promising technology breakthroughs and how the industry can introduce improved approaches during drug development.


The impressive line-up includes an opening keynote: ‘Minimizing CMC Risk to Maximize Probability of Success’ from Anthony A. McKinney; founder, president & CEO of Ethismos and founder and chief development officer of Neurovance, Inc.


Don Dickison, vice president, business development at event sponsor Juniper Pharma Services, said: “The forum will explore how consultants, CROs and CMOs must invest in their resources to meet the evolving demands of drug development.


“This includes informed discussion around some of the sector’s current hot topics including overcoming regulatory barriers, bringing innovative technologies and new approaches to the ‘CDMO world’ and the challenges of novel drug delivery.”


A distinguished panel of specialists that includes representatives from TetraScience, Covaris and Pion Inc. will discuss ‘Implementing the Impossible.’ Dickison added: “This is an exciting and innovative event and one which Juniper Pharma Services is proud to be part of. The caliber of the speakers and experts in attendance is second-to-none so will no doubt generate valuable discussion and learning for everyone involved.”


Manuel Sanchez-Felix, Ph.D., senior fellow, Novel Delivery Technologies, Novartis Institute for Biomedical Research and Padma Narayan, Ph.D., director, Formulation Development, Tech Ops Development, SAGE Therapeutics will also present on the day.


The closing keynote comes from Ibis Sánchez-Serrano, MBA, president & CEO of "The Core Model Corporation" (C.M.C.) and Calestous Juma, professor of the Practice of International Development, and director of the Science, Technology, and Globalization Project at the Belfer Center for Science and International Affairs of the Harvard Kennedy School who will discuss: ‘Breaking Down Barriers to Adoption of New Technology’.


The forum will be held at The Liberty Hotel in Boston. Click here for further information and registration.




For further information, images and interview opportunities with Juniper Pharma Services, please contact Rachael Heath at ramarketing | | +44 (0)7592342866 |


About Juniper Pharma Services


Juniper Pharma Services is a contract development and manufacturing organization (CDMO) specializing in science-led solutions for pharmaceutical development. The business provides expertise, R&D infrastructure and manufacturing capabilities to transform clients' promising molecules into successful products for unmet medical needs. Researching, developing and manufacturing new formulations for ground-breaking medicines is at the core of its services.


For more information, visit, follow on Twitter @JuniperServices or LinkedIn



Editor's Details

Lara Lovenbury

Last updated on: 16/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.